Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 3/2012

01-06-2012 | Review Article

Luminex and antibody detection in kidney transplantation

Authors: Antonietta Picascia, Teresa Infante, Claudio Napoli

Published in: Clinical and Experimental Nephrology | Issue 3/2012

Login to get access

Abstract

Preformed anti-human leukocyte antigen (HLA) antibodies have a negative effect on kidney transplantation outcome with an increased rejection rate and reduction in survival. Posttransplantation production of donor-specific anti-HLA antibodies is indicative of an active immune response and risk of transplantation rejection. For many years the primary technique for anti-HLA antibody detection was complement-dependent cytotoxicity (CDC), which has been integrated by solid-phase assays as HLA antigen-coated bead methods (Luminex). This new technological approach has allowed identification of anti-HLA antibodies, not detectable using conventional CDC method, in patients awaiting kidney transplantation. Moreover, use of Luminex technology has enabled better definition of acceptable or unacceptable antigens favoring transplantation in highly immunized patients. However, there are still many unresolved issues, including the clinical relevance of antibodies detected with this system.
Literature
1.
Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. New Engl J Med. 1969;280:735–9.PubMedCrossRef
2.
Terasaki PI. Humoral theory of transplantation. Am J Transpl. 2003;3:665–73.CrossRef
3.
Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;218:1398–406.CrossRef
4.
Kaneku H. Impact of donor-specific HLA antibodies in transplantation, a review of the literature published in the last three years. Clin Transpl. 2010;283–306.
5.
Loupy A, Suberbielle-Boissel C, Hill GS, Lefaucheur C, Anglicheau D, Zuber J, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transpl. 2009;9:2561–70.CrossRef
6.
Lachmann N, Terasaki PI, Budde K, Liefeldt L, Kahl A, Reinke P, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation. 2009;87:1505–13.PubMedCrossRef
7.
Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation. 2009;88:568–74.PubMedCrossRef
8.
Zhu L, Lee PC, Everly MJ, Terasaki PI. Detailed examination of HLA antibody development on renal allograft failure and function. Clin Transpl. 2008;171–87.
9.
Gloor JM. The utility of comprehensive assessment of donor specific anti-HLA antibodies in the clinical management of pediatric kidney transplant recipients. Pediatr Transpl. 2011;15:557–63.
10.
Kao KJ, Scornik JC, Small SJ. Enzyme-linked immunoassay for anti-HLA antibodies—an alternative to panel studies by lymphocytotoxicity. Transplantation. 1993;55:192–6.PubMedCrossRef
11.
Monien S, Salama A, Schönemann C. ELISA methods detect HLA antibodies with variable sensitivity. Int J Immunogenet. 2006;33:163–6.PubMedCrossRef
12.
Pajaro OE, George JF. On solid-phase antibody assays. J Heart Lung Transpl. 2010;29:1207–9.CrossRef
13.
Colombo MB, Haworth SE, Poli F, Nocco A, Puglisi G, Innocente A, et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B ClinCytom. 2007;72:465–71.CrossRef
14.
Ozawa M, Verbanac KM, Catrou P, Haisch CE, Terasaki PI. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development. Clin Transpl. 2006;241–53.
15.
El-Awar N, Lee J, Terasaki PI. HLA antibody identification with single antigen beads compared to conventional methods. Hum Immunol. 2005;66:989–97.PubMedCrossRef
16.
Arnold ML, Zacher T, Dechant M, Kalden JR, Doxiadis II, Spriewald BM. Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol. 2004;65:1288–96.PubMedCrossRef
17.
Zeevi A, Girnita A, Duquesnoy R. HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation. Immunol Res. 2006;36:255–64.PubMedCrossRef
18.
Zachary AA, Klingman L, Thorne N, Smerglia AR, Teresi GA. Variations of the lymphocytotoxicity test. An evaluation of sensitivity and specificity. Transplantation. 1995;60:498–503.PubMedCrossRef
19.
Tait BD. Solid phase assays for HLA antibody detection in clinical transplantation. Curr Opin Immunol. 2009;21:573–7.PubMedCrossRef
20.
Tait BD, Hudson F, Cantwell L, Brewin G, Holdsworth R, Bennett G, et al. Review article: luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton). 2009;14:247–54.CrossRef
21.
Pei R, Wang G, Tarsitani C, Rojo S, Chen T, Takemura S, et al. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol. 1998;59:313–22.PubMedCrossRef
22.
Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation. 2003;75:43–9.PubMedCrossRef
23.
Van den Berg-Loonen EM, Billen EV, Voorter CE, van Heurn LW, Claas FH, van Hooff JP, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation. 2008;85:1086–90.PubMedCrossRef
24.
Cecka JM. Current methodologies for detecting sensitization to HLA antigens. Curr Opin Organ Transpl. 2011;16:398–403.CrossRef
25.
Cai J, Terasaki PI. Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol. 2008;20:602–6.PubMedCrossRef
26.
El-Awar N, Terasaki PI, Cai J, Deng CT, Ozawa M, Nguyen A. Epitopes of the HLA-A, B, C, DR, DQ and MICA antigens. Clin Transpl. 2009;295–321.
27.
Deng CT, El-Awar N, Ozawa M, Cai J, Lachmann N, Terasaki PI. Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients. Transplantation. 2008;86:452–9.PubMedCrossRef
28.
Qiu J, Cai J, Terasaki PI, El-Awar N, Lee JH. Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads. Transplantation. 2005;80:1511–3.PubMedCrossRef
29.
Singh P, Colombe BW, Francos GC, Martinez Cantarin MP, Frank AM. Acute humoral rejection in a zero mismatch deceased donor renal transplant due to an antibody to an HLA-DP alpha. Transplantation. 2010;90:220–1.
30.
Gilbert M, Paul S, Perrat G, Giannoli C. Pouteil Noble C, Morelon E et al. Impact of pretransplant human leukocyte antigen-C and -DP antibodies on kidney graft outcome. Transpl Proc. 2011;43:3412–4.CrossRef
31.
Vaidya S, Hilson B, Sheldon S, Cano P, Fernandez-Vina M. DP reactive antibody in a zero mismatch renal transplant pair. Hum Immunol. 2007;68:947–9.PubMedCrossRef
32.
Thaunat O, Hanf W, Dubois V, McGregor B, Perrat G, Chauvet C, et al. Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. Transpl Immunol. 2009;20:209–11.PubMedCrossRef
33.
Billen EV, Christiaans MH, Doxiadis II, Voorter CE, van den Berg-Loonen EM. HLA-DP antibodies before and after renal transplantation. Tissue Antigens. 2010;75:278–85.PubMedCrossRef
34.
Duquesnoy RJ, Marrari M. Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants. Transpl Immunol. 2011;24:164–71.PubMedCrossRef
35.
Barabanova Y, Ramon DS, Tambur AR. Antibodies against HLA-DQ alpha-chain and their role in organ transplantation. Hum Immunol. 2009;70:410–2.PubMedCrossRef
36.
Bryan CF, Luger AM, Smith JL, Warady BA, Wakefield M, Schadde E, et al. Sharing kidneys across donor-service area boundaries with sensitized candidates can be influenced by HLA C. Clin Transpl. 2010;24:56–61.CrossRef
37.
Proust B, Kennel A, Ladrière M, Kessler M, Perrier P. Unexpected anti-HLA-DR and -DQ alloantibodies after nephrectomy of an HLA-DR and -DQ identical first renal transplant. Transpl Immunol. 2009;21:166–8.PubMedCrossRef
38.
Muro M, González-Soriano MJ, Salgado G, López R, Boix F, López M, et al. Specific “intra-allele” and “intra-broad antigen” human leukocyte antigen alloantibodies in kidney graft transplantation. Hum Immunol. 2010;71:857–60.PubMedCrossRef
39.
Cox ST, Stephens HA, Fernando R, Karasu A, Harber M, Howie AJ, et al. Major histocompatibility complex class I-related chain A allele mismatching, antibodies, and rejection in renal transplantation. Hum Immunol. 2011;72:827–34.PubMedCrossRef
40.
Narayan S, Tsai EW, Zhang Q, Wallace WD, Reed EF, Ettenger RB. Acute rejection associated with donor-specific anti-MICA antibody in a highly sensitized pediatric renal transplant recipient. Pediatr Transpl. 2011;15:E1–7.CrossRef
41.
Zachary AA, Montgomery RA, Leffell MS. Defining unacceptable HLA antigens. Curr Opin Organ Transpl. 2008;13:405–10.CrossRef
42.
Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtualcrossmatch. Hum Immunol. 2009;70:574–9.PubMedCrossRef
43.
Batal I, Zeevi A, Lunz JG 3rd, Aggarwal N, Shapiro R, Randhawa P, et al. Antihuman leukocyte antigen–specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med. 2010;134:1534–40.PubMed
44.
Billen EV, Christiaans MH, van den Berg-Loonen EM. Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants. Tissue Antigens. 2009;74:205–12.PubMedCrossRef
45.
Gandhi MJ, Degoey SR, Bundy K, Kremers WK, Knauer R, Pereira N, et al. Effect of pretransplant human leukocyte antigen antibodies detected by solid-phase assay on heart transplant outcomes. Transplant Proc. 2011;43(10):3840–6.PubMedCrossRef
46.
Billen EV, Voorter CE, Christiaans MH, van den Berg-Loonen EM. Luminex donor-specific crossmatches. Tissue Antigens. 2008;71:507–13.PubMedCrossRef
47.
Caro-Oleas JL, González-Escribano MF, Toro-Llamas S, Acevedo MJ, Martinez-Bravo MJ, Aguilera I, et al. Donor-specific antibody detection: comparison of single antigen assay and Luminex crossmatches. Tissue Antigens. 2010;76:398–403.PubMedCrossRef
48.
Caro-Oleas JL, González-Escribano MF, González-Roncero FM, Acevedo-Calado MJ,Cabello-Chaves V, Gentil-Govantes MA et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transpl. 2011 [Epub ahead of print].
49.
Riethmüller S, Ferrari-Lacraz S, Müller MK, Raptis DA, Hadaya K, Rüsi B, et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation. 2010;90:160–7.PubMedCrossRef
50.
Leffell MS, Zachary AA. Antiallograft antibodies: relevance, detection, and monitoring. Curr Opin Organ Transpl. 2010;15:2–7.CrossRef
51.
Minucci PB, Grimaldi V, Casamassimi A, Cacciatore F, Sommese L, Picascia A, et al. Methodologies for Anti-HLA antibody screening in patients awaiting kidney transplant: a comparative study. Exp Clin Transpl. 2011;9(6):381–6.
52.
Poli F, Cardillo M, Scalamogna M. Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach. Hum Immunol. 2009;70:631–5.PubMedCrossRef
53.
Gupta A, Sinnott P. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor. Hum Immunol. 2009;70:618–22.PubMedCrossRef
54.
Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation. 2008;85:1200–4.PubMedCrossRef
55.
Eng HS, Bennett G, Bardy P, Coghlan P, Russ GR, Coates PT. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum Immunol. 2009;70:595–9.PubMedCrossRef
56.
Aubert V, Venetz JP, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol. 2009;70:580–3.PubMedCrossRef
57.
Opelz G, Claas FH. Which human leukocyte antigen antibodies are really clinically relevant? Hum Immunol. 2009;70:561–2.PubMedCrossRef
58.
Zoet YM, Brand-Schaaf SH, Roelen DL, Mulder A, Claas FH, Doxiadis II. Challenging the golden standard in defining donor-specific antibodies: does the solid phase assay meet the expectations? Tissue Antigens. 2011;77:225–8.PubMedCrossRef
59.
Vlad G, Ho EK, Vasilescu ER, Colovai AI, Stokes MB, Markowitz GS, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol. 2009;70:589–94.PubMedCrossRef
60.
Pereira S, Perkins S, Lee JH, Shumway W, LeFor W, Lopez-Cepero M et al. Donor-specific antibody against denatured HLA-A1: clinically nonsignificant? Hum Immunol. 2011;72:492–8.
61.
Taylor CJ, Kosmoliaptsis V, Summers DM, Bradley JA. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol. 2009;70:563–8.PubMedCrossRef
62.
Mizutani K, Terasaki P, Hamdani E, Esquenazi V, Rosen A, Miller J, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transpl. 2007;7:1027–31.CrossRef
63.
Vaidya S, Partlow D, Susskind B, Noor M, Barnes T, Gugliuzza K. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation. 2006;82:1524–8.PubMedCrossRef
64.
Wahrmann M, Exner M, Schillinger M, Haidbauer B, Regele H, Körmöczi GF, et al. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transpl. 2006;6:1033–41.CrossRef
65.
Wahrmann M, Exner M, Haidbauer B, Schillinger M, Regele H, Körmöczi G, et al. [C4d]FlowPRA screening–a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum Immunol. 2005;66:526–34.PubMedCrossRef
66.
Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, luminex binding antibodies—a new tool for prediction of graft failure after heart transplantation. Am J Transpl. 2007;7:2809–15.CrossRef
67.
Heinemann FM, Roth I, Rebmann V, Arnold ML, Witzke O, Wilde B, et al. Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. Hum Immunol. 2007;68:500–6.PubMedCrossRef
68.
Arnold ML, Dechant M, Doxiadis II, Spriewald BM. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. Tissue Antigens. 2008;72:60–6.PubMedCrossRef
69.
Bartel G, Wahrmann M, Exner M, Regele H, Huttary N, Schillinger M, et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transpl. 2008;8:41–9.CrossRef
70.
Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transpl. 2011;30:158–63.CrossRef
71.
Hönger G, Wahrmann M, Amico P, Hopfer H, Böhmig GA, Schaub S. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation. 2010;89:1471–5.PubMedCrossRef
72.
Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol. 2011;72:849–58.PubMedCrossRef
Metadata
Title
Luminex and antibody detection in kidney transplantation
Authors
Antonietta Picascia
Teresa Infante
Claudio Napoli
Publication date
01-06-2012
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2012
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0635-1

Other articles of this Issue 3/2012

Clinical and Experimental Nephrology 3/2012 Go to the issue

Case Report

Matrix metalloproteinase levels in peritoneal effluents were increased in a patient with appendicitis undergoing continuous ambulatory peritoneal dialysis

Original Article

Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases

Original Article

Characteristics of spontaneous calcium oscillations in renal tubular epithelial cells

Original Article

Persistently low intact parathyroid hormone levels predict a progression of aortic arch calcification in incident hemodialysis patients

Original Article

Serum albumin level accurately reflects antioxidant potentials in idiopathic nephrotic syndrome

Original Article

Home systolic blood pressure on the morning of dialysis days has prognostic impact for hypertensive hemodialysis patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits